March 4, 2024 06:29 AM ESTUpdated 10:07 AM
R&D

Akero re­turns with more MASH da­ta to back PhI­II drug, touts fi­bro­sis re­sponse rate

Ayisha Sharma

News Reporter

Akero Ther­a­peu­tics is back with more da­ta for its FGF21 ana­log in meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH), a dis­ease space that’s been

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times